{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:44:05Z","timestamp":1793454245138,"version":"4.5.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2002889"],"award-info":[{"award-number":["2002889"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1183273"],"award-info":[{"award-number":["1183273"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002129","name":"Heart Foundation","doi-asserted-by":"publisher","award":["105609"],"award-info":[{"award-number":["105609"]}],"id":[{"id":"10.13039\/100002129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dual antiplatelet therapy with P2Y12 inhibitors (P2Y12i) and aspirin following acute myocardial infarction (AMI) prevents future ischaemic events. People with atrial fibrillation (AF) also require oral anticoagulants (OAC), increasing bleeding risk. Guidelines recommend post-discharge prescribing of direct OAC with clopidogrel and discontinuation of P2Y12i after 12 months, but little is known about use in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To describe post-discharge use of OACs and P2Y12i in people with AF and a history of OAC use hospitalized for AMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We identified 1330 people hospitalized for AMI with a diagnosis of AF and history of OAC use in New South Wales, Australia, July 2018\u2013June 2020. We identified three aspects of post-discharge antithrombotic medicine use with possible safety implications: (1) not being dispensed OACs; (2) dispensing OAC and P2Y12i combinations associated with increased bleeding (involving warfarin, ticagrelor, or prasugrel); and (3) P2Y12i use longer than 12 months.<\/jats:p>\n                    <jats:p>After discharge, 74.3% of people were dispensed an OAC, 45.4% were dispensed a P2Y12i, and 35.8% were dispensed both. People with comorbid heart failure or cancer were less likely to receive OACs. Only 11.2% of people who dispensed both an OAC and P2Y12i received combinations associated with increased bleeding; this was more common among people with chronic kidney disease or prior warfarin or statin use. A total of 44.6% of people dispensed both medicines continued P2Y12i for over 12 months; this was more common in people who received a revascularization or lived in areas of social disadvantage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We identified potential gaps in pharmacotherapy, including underuse of recommended therapies at discharge, use of combinations associated with increased bleeding, and P2Y12i use beyond 12 months. Prescribing vigilance across both hospital and community care is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcae068","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T01:58:58Z","timestamp":1723168738000},"page":"259-270","source":"Crossref","is-referenced-by-count":5,"title":["Post-discharge pharmacotherapy in people with atrial fibrillation hospitalized for acute myocardial infarction: an Australian cohort study 2018\u201322"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-5801","authenticated-orcid":false,"given":"Claire T","family":"Deakin","sequence":"first","affiliation":[{"name":"Medicines Intelligence Centre of Research Excellence, School of Population Health, Faculty of Medicine and Health, UNSW Sydney , Sydney 2052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-023X","authenticated-orcid":false,"given":"Juliana de Oliveira","family":"Costa","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Centre of Research Excellence, School of Population Health, Faculty of Medicine and Health, UNSW Sydney , Sydney 2052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-0326","authenticated-orcid":false,"given":"David","family":"Brieger","sequence":"additional","affiliation":[{"name":"Concord Repatriation General Hospital Department of Cardiology, , Sydney 2139 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-9191","authenticated-orcid":false,"given":"Jialing","family":"Lin","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Centre of Research Excellence, School of Population Health, Faculty of Medicine and Health, UNSW Sydney , Sydney 2052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-4997","authenticated-orcid":false,"given":"Andrea L","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, University of Oxford Nuffield Department of Primary Care Health Sciences, , Oxford OX2 6GG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-1245","authenticated-orcid":false,"given":"Michael","family":"Kidd","sequence":"additional","affiliation":[{"name":"Centre for Future Health Systems, Faculty of Medicine and Health, UNSW Sydney , Sydney 2052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-6855","authenticated-orcid":false,"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Centre of Research Excellence, School of Population Health, Faculty of Medicine and Health, UNSW Sydney , Sydney 2052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6444-7272","authenticated-orcid":false,"given":"Michael O","family":"Falster","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Centre of Research Excellence, School of Population Health, Faculty of Medicine and Health, UNSW Sydney , Sydney 2052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"2025050111115729800_bib1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.5694\/MJA16.00368","article-title":"National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016","volume":"205","author":"Chew","year":"2016","journal-title":"Med J Aust"},{"key":"2025050111115729800_bib2","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404\/-\/DC2","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"2025050111115729800_bib3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/EURHEARTJ\/EHX419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2025050111115729800_bib4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/EURHEARTJ\/EHX393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2025050111115729800_bib5","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"2025050111115729800_bib6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/nejmoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2025050111115729800_bib7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2025050111115729800_bib8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet North Am Ed"},{"key":"2025050111115729800_bib9","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/nejmoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2025050111115729800_bib10","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1161\/CIR.0000000000001038","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"2025050111115729800_bib11","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/nejmoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2025050111115729800_bib12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"2025050111115729800_bib13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2025050111115729800_bib14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set oversight Committee","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025050111115729800_bib15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025050111115729800_bib16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/ehjacc\/zuad107","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"13","author":"Byrne","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2025050111115729800_bib17","doi-asserted-by":"publisher","first-page":"qcw051","DOI":"10.1093\/ehjqcco\/qcw051","article-title":"Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study","volume":"3","author":"Russo","year":"2017","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025050111115729800_bib18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ijcard.2016.11.240","article-title":"Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: insights from the Canadian Observational AntiPlatelet sTudy","volume":"228","author":"Bagai","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025050111115729800_bib19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1253\/circj.CJ-18-1283","article-title":"Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a real-world observation in Taiwan from 2012 to 2015","volume":"83","author":"Li","year":"2019","journal-title":"Circ J"},{"key":"2025050111115729800_bib20","doi-asserted-by":"publisher","first-page":"e028114","DOI":"10.1136\/bmjopen-2018-028114","article-title":"Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain)","volume":"9","author":"Ribera","year":"2019","journal-title":"BMJ Open"},{"key":"2025050111115729800_bib21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjcard.2021.08.055","article-title":"Outcomes in patients stratified by PRECISE-DAPT versus DAPT scores after percutaneous coronary interventions","volume":"161","author":"Boudreau","year":"2021","journal-title":"Am J Cardiol"},{"key":"2025050111115729800_bib22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/eurheartj\/ehac116","article-title":"P2Y12 inhibitor adherence trajectories in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prognostic implications","volume":"43","author":"Turgeon","year":"2022","journal-title":"Eur Heart J"},{"key":"2025050111115729800_bib23","doi-asserted-by":"publisher","first-page":"1106503","DOI":"10.3389\/fcvm.2023.1106503","article-title":"Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014\u20132019)","volume-title":"Front Cardiovasc Med","author":"Mezier","year":"2023"},{"key":"2025050111115729800_bib24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/IMJ.15036","article-title":"Evidence-practice gaps in P2Y12 inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population-level data linkage in Australia","volume":"52","author":"Falster","year":"2022","journal-title":"Intern Med J"},{"key":"2025050111115729800_bib25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00059-022-05099-6","article-title":"Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany","volume":"48","author":"Zeymer","year":"2023","journal-title":"Herz"},{"key":"2025050111115729800_bib26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jjcc.2023.03.004","article-title":"Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: insights from the CONNECT AF\u202f+\u202fPCI-II program","volume":"82","author":"Chow","year":"2023","journal-title":"J Cardiol"},{"key":"2025050111115729800_bib27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/FJC.0000000000000973","article-title":"Real-world experience with antiplatelet agents after percutaneous coronary intervention in patients with an indication for an oral anticoagulant","volume":"77","author":"Tanner","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025050111115729800_bib28","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/J.JCLINEPI.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2025050111115729800_bib29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2025050111115729800_bib30","article-title":"Medication use for secondary prevention after coronary heart disease hospitalisations: patient pathways using linked data","author":"Australian Institute of Health and Welfare","year":"2022"},{"key":"2025050111115729800_bib31","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/PDS.3459","article-title":"Assigning exposure duration to single prescriptions by use of the waiting time distribution","volume":"22","author":"Potteg\u00e5rd","year":"2013","journal-title":"Pharmacoepidemiol Drug"},{"key":"2025050111115729800_bib32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40264-014-0179-2","article-title":"Association between use of multiple psychoactive medicines and hospitalization for falls: retrospective analysis of a large healthcare claim database","volume":"37","author":"Pratt","year":"2014","journal-title":"Drug Saf"},{"key":"2025050111115729800_bib33","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1111\/bcp.13369","article-title":"Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study","volume":"83","author":"Brett","year":"2017","journal-title":"Brit J Clin Pharma"},{"key":"2025050111115729800_bib34","article-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2020"},{"key":"2025050111115729800_bib35","article-title":"A package for survival analysis in R","author":"Therneau"},{"key":"2025050111115729800_bib36","doi-asserted-by":"publisher","first-page":"e013000","DOI":"10.1161\/CIRCINTERVENTIONS.122.013000","article-title":"Risk burden of cancer in patients treated with abbreviated dual antiplatelet therapy after PCI: analysis of multicenter controlled high-bleeding Risk trials","volume":"17","author":"Campos","year":"2024","journal-title":"Circ Cardiovascular Interventions"},{"key":"2025050111115729800_bib37","first-page":"886","article-title":"Communication at the interface between hospitals and primary care: a general practice audit of hospital discharge summaries","volume":"42","author":"Belleli","year":"2013","journal-title":"Aust Fam Phys"},{"key":"2025050111115729800_bib38","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/imj.12581","article-title":"Transition from hospital to primary care: an audit of discharge summary\u2014medication changes and follow-up expectations","volume":"44","author":"Tan","year":"2014","journal-title":"Intern Med J"},{"key":"2025050111115729800_bib39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1071\/PY22232","article-title":"Medication reconciliation and discharge communication from hospital to general practice: a quantitative analysis","volume":"29","author":"Gusmeroli","year":"2023","journal-title":"Aust J Prim Health"},{"key":"2025050111115729800_bib40","doi-asserted-by":"publisher","first-page":"e063282","DOI":"10.1136\/bmjopen-2022-063282","article-title":"Association between continuity of primary care and both prescribing and adherence of common cardiovascular medications: a cohort study among patients in England","volume":"12","author":"Tammes","year":"2022","journal-title":"BMJ Open"},{"key":"2025050111115729800_bib41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/ejhpharm-2016-000967","article-title":"Deprescribing: a primary care perspective","volume":"24","author":"Duncan","year":"2017","journal-title":"Eur J Hosp Pharm"},{"key":"2025050111115729800_bib42","doi-asserted-by":"crossref","first-page":"bjgpopen20X101096","DOI":"10.3399\/bjgpopen20X101096","article-title":"Barriers and facilitators to deprescribing in primary care: a systematic review","volume":"4","author":"Doherty","year":"2020","journal-title":"BJGP Open"},{"key":"2025050111115729800_bib43","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/imj.14706","article-title":"Clinical decision support in a hospital electronic prescribing system informed by local data: experience at a tertiary New Zealand centre","volume":"50","author":"Chin","year":"2020","journal-title":"Intern Med J"},{"key":"2025050111115729800_bib44","doi-asserted-by":"publisher","first-page":"e6206","DOI":"10.1111\/hsc.14058","article-title":"Factors which influence the deprescribing decisions of community-living older adults and GPs in Australia","volume":"30","author":"Gillespie","year":"2022","journal-title":"Health Social Care Comm"},{"key":"2025050111115729800_bib45","article-title":"Aged care on-site pharmacist","author":"Australian Government Department of Health and Aged Care","year":"2024"},{"key":"2025050111115729800_bib46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12928-019-00633-6","article-title":"Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective","volume":"35","author":"Saito","year":"2020","journal-title":"Cardiovasc Interv and Ther"},{"key":"2025050111115729800_bib47","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"2025050111115729800_bib48","doi-asserted-by":"publisher","first-page":"e02","DOI":"10.15420\/ECR.2020.40","article-title":"2020 Asian Pacific Society of Cardiology consensus recommendations on the use of P2Y12 receptor antagonists in the Asia-Pacific region","volume":"16","author":"Tan","year":"2021","journal-title":"Eur Cardiol"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcae068\/59035517\/qcae068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/11\/3\/259\/59035517\/qcae068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/11\/3\/259\/59035517\/qcae068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:12:05Z","timestamp":1746097925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/11\/3\/259\/7730316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,8]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcae068","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,8,8]]}}}